Crestor and Bupropion Interaction: What Prescribers and Patients Should Know

Why This Combination Raises Questions

Patients prescribed a statin for cholesterol and an antidepressant for mood or smoking cessation often ask whether the two drugs conflict. That concern is reasonable. Statins as a class carry a dose-dependent risk of myopathy and rhabdomyolysis, and drugs that raise statin plasma concentrations can push that risk higher [1]. Bupropion is a known inhibitor of cytochrome P450 2D6 (CYP2D6), which raises a logical follow-up question: does blocking CYP2D6 cause rosuvastatin to accumulate?

The short answer is no. Rosuvastatin's metabolic pathway barely touches CYP2D6. The FDA-approved prescribing information for rosuvastatin states that it undergoes limited metabolism, with CYP2C9 responsible for the primary (though minor) oxidative biotransformation [2]. Roughly 90% of an oral dose is eliminated unchanged in feces, meaning hepatic uptake transporters (OATP1B1 and BCRP) govern exposure far more than any CYP enzyme [3]. Bupropion does not inhibit these transporters at therapeutic concentrations, so the pharmacokinetic paths of these two drugs run in parallel rather than colliding.

Rosuvastatin Pharmacokinetics: A Statin That Sidesteps Most CYP Interactions

Rosuvastatin differs from older statins in a way that matters for drug interactions. Simvastatin and atorvastatin depend heavily on CYP3A4 for metabolism, which is why grapefruit juice warnings and azole antifungal precautions apply to those agents [4]. Rosuvastatin does not.

After oral dosing, rosuvastatin reaches peak plasma concentration in about 3 to 5 hours with a bioavailability of approximately 20% [2]. The liver takes up the drug through OATP1B1 and OATP1B3 solute carriers. Once inside the hepatocyte, the drug inhibits HMG-CoA reductase (its target) and is then exported, largely unchanged, via BCRP (ABCG2) into bile [3]. CYP2C9 produces a minor N-desmethyl metabolite, but this pathway accounts for less than 10% of total clearance [2]. CYP2D6, CYP3A4, and CYP1A2 play no meaningful role.

This transport-dominant clearance is why the FDA label for rosuvastatin lists OATP1B1 inhibitors (cyclosporine, certain protease inhibitors) as the drugs most likely to increase rosuvastatin exposure, not CYP inhibitors [2]. A 2017 genome-wide pharmacokinetic study (N=301) confirmed that SLCO1B1 polymorphisms (the gene encoding OATP1B1) explained the largest share of interindividual variability in rosuvastatin AUC, reinforcing that transporter biology, not CYP metabolism, drives exposure differences [5].

Bupropion Pharmacokinetics: Where Its Inhibition Actually Lands

Bupropion is metabolized primarily by CYP2B6 to its active metabolite hydroxybupropion [6]. It is also a potent competitive inhibitor of CYP2D6, with an estimated in vivo inhibition constant (Ki) that produces clinically relevant effects on CYP2D6 substrates. The FDA label for bupropion warns that co-administration with CYP2D6 substrates such as desipramine, metoprolol, and nortriptyline can increase their plasma levels by two- to fivefold [6].

This matters for drugs cleared through CYP2D6. It does not matter for rosuvastatin. A 2015 systematic review of statin-antidepressant interactions published in the Journal of Clinical Pharmacology found no pharmacokinetic signal between bupropion and any hydrophilic statin (rosuvastatin, pravastatin) [7]. The review noted that interaction risk concentrates on lipophilic statins metabolized through CYP3A4 or CYP2D6, neither of which applies to rosuvastatin.

Bupropion's other pharmacological actions (norepinephrine-dopamine reuptake inhibition, nicotinic receptor antagonism) do not overlap with statin pharmacodynamics in a way that creates additive toxicity. Bupropion does lower the seizure threshold in a dose-dependent manner, but rosuvastatin has no known effect on seizure susceptibility [6].

Formal Interaction Classification

Major drug interaction databases classify the rosuvastatin-bupropion pair consistently.

The Lexicomp database rates this combination as having no significant interaction requiring monitoring beyond standard care. The Clinical Pharmacology database concurs, listing no expected change in the pharmacokinetics or pharmacodynamics of either agent. The FDA labels for both drugs do not mention the other by name [2][6].

For clinical decision-making, a practical framework for evaluating any statin-antidepressant pair involves three questions: (1) Does the antidepressant inhibit a CYP isoform the statin depends on? (2) Does the antidepressant inhibit OATP1B1 or BCRP? (3) Is there a pharmacodynamic overlap that raises toxicity risk (e.g., QT prolongation, serotonin-mediated myopathy)? For bupropion and rosuvastatin, all three answers are no.

When Caution Is Still Warranted

The absence of a direct interaction does not eliminate all clinical considerations. Several scenarios deserve attention.

Polypharmacy with a hidden CYP bridge. If a patient takes rosuvastatin, bupropion, and a third drug that inhibits OATP1B1 (for example, elbasvir/grazoprevir for hepatitis C), rosuvastatin levels could climb for reasons unrelated to bupropion [2]. Clinicians should evaluate the full medication list, not just the two-drug pair.

Shared hepatotoxicity signals. Rosuvastatin carries a rare risk of hepatotoxicity, with the label recommending liver function tests before initiation and as clinically indicated [2]. Bupropion undergoes extensive hepatic metabolism and has been associated with rare hepatic injury reported in post-marketing surveillance [6]. In patients with pre-existing liver disease or alcohol use disorder, monitoring ALT and AST at baseline and at 12 weeks after starting either drug is a reasonable practice.

Muscle symptom attribution. Bupropion can cause musculoskeletal complaints (reported in 2% to 6% of clinical trial participants) [6]. Statins carry their own muscle-related adverse effect profile. When a patient on both drugs reports new myalgia, clinicians need to measure creatine kinase (CK) and consider whether symptoms align with statin-associated muscle symptoms (SAMS) criteria defined by the 2014 National Lipid Association task force [8]. Do not reflexively attribute all muscle pain to the statin.

Genetic outliers. Patients who are CYP2C9 poor metabolizers have modestly higher rosuvastatin exposure [5]. If such a patient also takes bupropion, the CYP2D6 inhibition is still irrelevant to rosuvastatin levels, but the prescriber should be aware that the patient may already sit at the higher end of the exposure curve. The CPIC guidelines for statins and SLCO1B1 (2022 update) recommend considering lower statin starting doses in patients carrying two decreased-function SLCO1B1 alleles, regardless of concomitant medications [9].

Dose-Adjustment Guidance

No dose adjustment of rosuvastatin is required when adding bupropion, and no dose adjustment of bupropion is required when adding rosuvastatin. This applies to all approved formulations:

• Rosuvastatin immediate-release tablets (5 mg, 10 mg, 20 mg, 40 mg)
• Bupropion immediate-release, sustained-release (SR), and extended-release (XL) formulations (75 mg to 450 mg daily)

The 40 mg dose of rosuvastatin, which the FDA restricts to patients who have not reached LDL-C goals on 20 mg, carries its own elevated myopathy risk [2]. That risk is intrinsic to the dose and is not compounded by bupropion co-administration. Patients on rosuvastatin 40 mg should receive CK monitoring per the label regardless of their antidepressant regimen.

Comparing Rosuvastatin to Other Statins in This Context

Not all statin-bupropion combinations are this straightforward. The distinction matters for patients who might switch statins.

Simvastatin and lovastatin are metabolized extensively by CYP3A4, making them vulnerable to interactions with CYP3A4 inhibitors but not with bupropion (a CYP2D6 inhibitor) [4]. Atorvastatin also uses CYP3A4 but is less sensitive than simvastatin to moderate inhibitors due to its longer half-life and multiple metabolic pathways [4].

Fluvastatin is metabolized by CYP2C9, the same minor pathway for rosuvastatin [4]. Bupropion does not inhibit CYP2C9, so fluvastatin-bupropion is also low risk.

Pitavastatin, like rosuvastatin, has minimal CYP metabolism and depends on OATP1B1 for hepatic uptake [10]. It shares rosuvastatin's favorable interaction profile with bupropion.

The practical takeaway: if a patient needs both a statin and bupropion, rosuvastatin and pitavastatin offer the cleanest pharmacokinetic profiles, but even simvastatin and atorvastatin have no direct interaction pathway with bupropion specifically.

Monitoring Recommendations for the Combination

For patients taking rosuvastatin and bupropion concurrently, the following monitoring schedule aligns with current ACC/AHA lipid guidelines and the rosuvastatin FDA label [2][11]:

Before starting: Fasting lipid panel, ALT, AST, and CK at baseline. Document seizure history (relevant for bupropion safety, not for the interaction itself).

4 to 12 weeks after initiation: Repeat fasting lipid panel to assess LDL-C response. Repeat ALT if baseline was abnormal or if the patient has hepatic risk factors.

Ongoing: Annual lipid panel. CK only if the patient develops unexplained muscle pain, tenderness, or weakness. No routine CK monitoring is needed solely because of bupropion co-administration.

Patient counseling points: Instruct patients to report unexplained muscle pain, dark urine, or unusual fatigue. These are standard statin counseling points. Tell patients that bupropion and rosuvastatin do not conflict and that both medications should be continued as prescribed. Patients should not stop either drug without consulting their prescriber.

What the Evidence Does Not Cover

No published randomized controlled trial has studied the rosuvastatin-bupropion pair as a primary endpoint. The safety inference comes from well-characterized metabolic pathways, absence of case reports of harm, and consistency across interaction databases. A 2019 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) did not identify a disproportionate signal for myopathy or rhabdomyolysis in patients co-prescribed rosuvastatin and bupropion [12]. The reporting odds ratio for the combination was not elevated above that for rosuvastatin alone.

This is the typical evidence base for drug pairs that lack a mechanistic reason to interact. The absence of a signal, combined with a clear pharmacokinetic rationale for why no interaction should occur, supports the consensus rating of "no clinically significant interaction."

Patients prescribed rosuvastatin 10 mg to 20 mg daily alongside bupropion XL 150 mg to 300 mg daily can expect standard efficacy from both medications without a need for additional laboratory monitoring beyond guideline-directed statin care [2][11].